It is often important to incorporating covariate information in the design of clinical trials. In literature, there are many designs of using stratification and covariate-adaptive randomization to balance on certain known covariate. Recently Zhang, Hu, Cheung and Chan (2007) have proposed a family of covariate-adjusted response-adaptive (CARA) designs and studied their asymptotic properties. However, these CARA designs often have high variabilities. In this paper, we propose a new family of covariate-adjusted response-adaptive (CARA) designs. We show that the new designs have smaller variabilities and therefore more efficient.
Introduction
Response-adaptive designs for clinical trials incorporate sequentially accruing response data into future allocation probabilities. A major objective of response-adaptive designs in clinical trials is to minimize the number of patients that is assigned to the inferior treatment to a degree that still generates useful statistical inferences. The preliminary idea of response adaptive randomization can be traced back to Thompson (1933) and Robbins (1952) . A lot of response-adaptive designs have been proposed in literature (e.g., Lachin 2002, Hu and . Much recent work has focused on proposing better randomized adaptive designs. The three main components for evaluating a response-adaptive design are allocation proportion, efficiency (power), and variability. The issue of efficiency or power was discussed by Hu and Rosenberger (2003) , who showed that the efficiency is a decreasing function of the variability induced by the randomization procedure for any given allocation proportion. Hu, Rosenberger and Zhang (2006) showed that there is an asymptotic lower bound on the variability of response-adaptive designs. A response-adaptive design that attains this lower bound will be said to be first order efficient. More recently, Hu, Zhang and He (2008) proposed a new family of efficient randomized adaptive designs that can adapt to any desired allocation proportion. But all these studies are limit to the designs that do not incorporate covariates.
In many clinical trials (Pocock and Simon, 1975, Taves, 1974) , covariate information is available and has a strong influence on the responses of patients. For instance, the efficacy of a hypertensive drug is related to a patient's initial blood pressure and cholesterol level, whereas the effectiveness of a cancer treatment may depend on whether the patient is a smoker or a non-smoker. Covariate-adaptive designs have been proposed to balance covariates among treatment groups (see Pocock and Simon, 1975 , Taves, 1974 and Zelen, 1974 . defined a covariate-adjusted response-adaptive (CARA) design as a design that incorporate sequentially history information of accruing response data and covariate as well as the observed covariate information of the incoming patient into future allocation probabilities.
In a CARA design, the assignment of a treatment depends on the history information and the covariate of the incoming patient. This generates a certain level of technical complexity for studying the properties of the design. Zhang, et al (2007) got a limit success on CARA designs by proposing a class of CARA designs that allow a wide spectrum of applications to very general statistical models and obtaining the asymptotic properties to provide a statistical basis for inferences after using this kind of designs. However, the CARA designs in Zhang, et al (2007) often have high variabilities and therefore are not efficient (Hu and Rosenberger, 2003) . The major purpose of this paper is to study the variability and efficiency of CARA designs and to propose a new family of CARA designs with small variabilities.
The paper is organized as follows. In Section 2, the Fisher information and the best asymptotic variability are derived for a CARA design with any given target allocation proportion. We will find that the Fisher information and the variability depend on the distribution of each individual response, the target function and the distribution of the covariate. In Section 3, we propose a new CARA design that can adapt to target any allocation function and in which a parameter can be tuned such that the asymptotic variability approaches to the best one. The design proposed by Zhang, et al (2007) is a special case of this new design and has the largest variability in all this kind of designs. The new design is also an extension of the doubly adaptive biased coin design (BDCD) proposed by Eisele and Woodroofe (1995) and Hu and Zhang (2004a) . The technical proofs are put on the Appendix.
2 Variability and efficiency of CARA designs
General framework of CARA designs.
Given a clinical trial with K treatments. Supposing that a patient with a covariate vector ξ is assigned to treatment k, k = 1, . . . , K, and the observed response is Y k , assume that the response Y k has a conditional distribution f k (y k |θ k , ξ) for given the covariate ξ. Here θ k , k = 1, . . . , K, are unknown parameters, and Θ k ⊂ R d is the parameter space of θ k .
In an adaptive design, we let X 1 , X 2 , ... be the sequence of random treatment assignments. For the m-th subject, X m = (X m,1 , . . . , X m,K ) represents the assignment of treatment such that if the m-th subject is allocated to treatment k, then all elements in X m are 0 except for the k-th component, 
. . , ξ m ) be the sigma fields corresponding to the responses, assignments and covariates respectively, and let F m = σ(X m , Y m , Z m ) be the sigma field of the history. A general covariate-adjusted responseadaptive (CARA) design is defined by
the conditional probabilities of assigning treatments 1, ..., K to the mth patient, conditioning on the entire history including the information of all previous m assignments, responses, and covariate vectors, plus the information of the current patient's covariate vector.
CARA designs with a target.
Let N m,k be the number of subjects assigned to treatment k in the first m assignments and write
Further, let N n,k|x = n m=1 X m,k I{ξ m = x} be the number of subjects with covariate x that is randomized to treatment k, k = 1, . . . , K, in the n trials, and N n (x) = n m=1 I{ξ m = x} be the total number of subjects with covariate x. Write θ = (θ 1 , . . . , θ K ). Because the value of θ and the covariate determinate the distributions of the outcomes, and accordingly, the effects of each treatments, in many cases one would like to define a CARA design such that the "conditional" allocation proportion for a given covariate x converges to a pre-specified proportion which is a function of θ and x. That is,
where (2007) developed a general framework to obtain optimal allocation proportion for K-treatment clinical trials. However, when P(ξ = x) = 0, for example, in the continuous covariate case, the "conditional" allocation proportion N n,k|x /N n (x) is not well-defined because both the numerator and denominator are zeros almost surely. As compared with (2.1), it is more meaningful to allocate each individual patient to treatment k with a probability close to π k (θ, x) for a given covariate x. So we consider a class of CARA designs with a property that
The next theorem tells us that (2.2) implies (2.1). Write
Here, "A a.s. on B" means that P(B \ A) = 0 for two events A and B.
Further, if the density of the covariate is positive at x, then
where
I{ξ m ∈ B(x, r)}, B(x, r) is a ball with the center x and the radius r.
Notice, when P(ξ = x) = 0, though the allocation proportion N n,k|x /N n (x) is not well-defined, (2.3) is trivial because P(N n (x) → ∞) = 0. Accurately, (2.3) makes sense only in the discrete covariate case and (2.5) is a version of (2.3) for continuous covarites.
Variability and efficiency.
For response-adaptive designs which do not incorporate covariates, Hu, Rosenberger and Zhang (2006) found the lower bound of the asymptotic variability of a design, i.e., of the allocation proportions of the design. A design is called asymptotically efficient if its asymptotic variability attains the lower bound. Next, we study the variability and efficiency of the CARA designs. Suppose, given ξ, that the response Y k of a trial of treatment k has a distribution in the exponential family, and takes the form
and, given ξ, the conditional Fisher information matrix is
For the observations up to stage n, the likelihood function is
It follows that the entire Firsher information matrix is
Thus we obtain the following theorem.
Theorem 2.2 Suppose the responses follow the generalized linear model (2.6) and the design satisfies (2.2). Let I(θ) = diag(I 1 , . . . , I K ). Then the Firsher information matrix satisfies
and the asymptotic variance-covariance matrix of an asymptotic efficient estimator of θ is I −1 (θ)/n.
The limit proportion ρ(θ) = (ρ 1 (θ), . . . , ρ K (θ)) depends on both the
The allocation proportion N n /n in a adaptive design with property (2.2) will converge to ρ(θ) according to Theorem 2.1. So we can now define an asymptotically efficient CARA design as follows.
Definition 1 A covaraite-adjusted response-adaptive design with target function π(θ, x) is called asymptotically efficient if it satisfies (2.2) and 9) and B(θ) is called the best asymptotic variability.
Zhang, Hu, Cheung and Chan (2007) proposed a CARA design (we refer it as ZHCC's design) by defining
where θ m is the MLE of θ based on the observations up to stage m. It has been shown that ZHCC's design satisfy (2.2) and
It is easily seen that
where A ≥ B means that A − B is non-negative definite. Hence, ZHCC's design is not asymptotically efficient. It is of significance to find an asymptotic efficient CARA design for any given target function π(θ, x). In the next section, we will propose a new class of CARA designs with an asymptotic variability being able to approach the best one.
Covariate-adjusted DBCD
Our new design is based on the idea of the doubly adaptive biased coin design (BDCD) proposed by Eisele and Woodroofe (1995) , and extended by Hu and Zhang (2004a) . In the scenario without covariates, the Hu and Zhang's extension can target any desired allocation and can approach the lower bound of the asymptotic variability by tuning a parameter. In this section, we modify the DBCD to incorporate covariates. For simplification, we only consider the two-treatment case (K = 2). Covariate-adjusted DBCD (CADBCD): To start, we let θ 0 be an initial estimate of θ, and assign m 0 subjects to each treatment by using a restricted randomization. Assume that m (m ≥ 2m 0 ) subjects have been assigned to treatments. Their responses {Y j , j = 1, . . . , m} and the corresponding covariates {ξ j , j = 1, . . . , m} are observed. We let θ m = ( θ m,1 , θ m,2 ) be an estimate of θ = (θ 1 , θ 2 ). Here, for each k = 1, 2, θ m,k = θ m,k (Y j,k , ξ j : X j,k = 1, j = 1, . . . , m) is the estimator of θ k that is based on the observed N m,k -size sample {(Y j,k , ξ j ) : for which X j,k = 1, j = 1 . . . , m}. Write ρ m = 1 m m i=1 π 1 ( θ m , ξ i ) and π m = π 1 ( θ m , ξ m+1 ). Next, when the (m + 1)-th subject is ready for randomization and the corresponding covariate ξ m+1 is recorded, we assign the patient to treatment 1 with a probability of
and to treatment 2 with a probability of ψ m+1,2 = 1 − ψ m+1,1 , where γ ≥ 0 is a constant that controls the degree of randomness of the procedure, from most random when γ = 0 to deterministic when γ = ∞. ZHCC's design is a special case of CADBCD with γ = 0.
Asymptotic properties.
For studying the asymptotic properties, we assume the target allocation function π 1 (θ * , x) satisfies the following condition.
Condition A We assume that the parameter space Θ k is a bounded domain in R d , and that the true value θ k is an interior point of Θ k , k = 1, 2.
1. For each fixed x, 0 < π 1 (θ * , x) < 1 is a continuous function of θ * in the closure of Θ 1 × Θ 2 .
2. π 1 (θ * , ξ) is twice differentiable with respect to θ * , and the expectations of ∂π 1 (θ, ξ)/∂θ 2 and sup θ * −θ ≤δ ∂ 2 π 1 (θ * , ξ)/∂θ 2 are finite for some
Theorem 3.1 Suppose that for k = 1, 2,
where h k s are functions with
Then under Condition A, we have (3.12) and
14)
The proof of this Theorem is a little complex and will be state in the Appendix. According to (3.12), CADBCD satisfies (2.2). The asymptotic variability σ 2 of the design takes the values from the maximum 2σ 2 3 +v(1−v) when γ = 0 to the minim σ 2 2 + σ 2 3 when γ = ∞.
The next result for the generalized linear model is a corollary of Theorem 3.1. The proof is given in the Appendix through the verification of Condition (3.11).
Corollary 3.1 Suppose the distributions of the responses follow the generalized linear model (2.6) and satisfy the following regular condition
Under Condition A, if the matrices I 1 and I 2 defined as in (2.8) are nonsingular and the MLE θ m , which maximize the likelihood function (2.7), is unique, then we have (3.12), (3.13), and (3.14) with V = I −1 (θ) and I(θ) = diag(I 1 , I 2 ).
It is obvious that B(θ) = σ 2 2 + σ 2 3 is the best asymptotic variability of CARA designs with two treatments according to Definition 1. For the CADBCD,
This means that the CADBCD is not asymptotically efficient but it can approach an asymptotically efficient CARA design if γ is chosen large. ZHCC's design is a special case of the CADBCD which has the largest variability.
Conclusion Remarks
We have proposed a family of covariate-adjusted response-adaptive designs that are fully randomized and asymptotically efficient. The CADBCD can be viewed as a generalization of Hu and Zhang's doubly adaptive biased coin design (Hu and Zhang, 2004a) for incorporating covariate information. The asymptotic properties derived here provide the theoretical foundation for inference based on the CADBCD.
In this paper, we have assumed that the responses in each treatment group are available without delay. In practice, there is no logistical difficulty in incorporating delayed responses into the CADBCD, provided that some responses become available during the course of the allocation in the experiment, and thus we can always update the estimates whenever new data become available. 
Appendix: Proofs
Proof of Theorem 2.1.
It follows that
by Theorem 3.3.10 of Stout (1974). On the other hand,
With a similar argument we have
Letting r ց 0 yields (2.5).
Proof of Theorem 3.1. The proof is a little complex and long. We will complete via four steps.
Step 1. We show that (3.13) and
. Then Q n and M n,j , j = 1, 2, 3, are martingales. According to the law of the iterated logarithm (LIL) for martingales, we have Q n = O( log log n/n) and M n,j = O( log log n/n) a.s.j = 1, 2, 3.
(5.17) Hence, by (3.11) it is easily shown that
It is easily shown that log log m m sup
Similarly,
It follows that π m = nv + O( n log log n) a.s.
It is easily seen that g(π, a, b) is a nondecreasing function of b, and so g(π, a, b)
≤nv + O( n log log n) a.s.
(3.13) and (5.16) are now proved.
Step 2. We show (3.12) and the asymptotic normality of θ n .
By (3.13) and (5.16), ρ n /(N n,1 /n) → 1 a.s.. And hence (3.12) is proved. and further ψ m,1 − π 1 ( θ m−1 , ξ m ) → 0 a.s. Then, it is easily check that Q n is a martingale with
So, applying the central limit theorem for martingales yields
The proof of Step 2 is completed.
Step 3. We show that
Let g(π, a, b) be defined as in (5.23). By some elementary argument, it can be showed that
. By (3.13) and (5.16), it follows that
(5.25) is now proved.
Step 4. At last, we show the asymptotic normality of N n . 
By (5.25) it follows that
On the other hand, 
x dx is a solution of the equation
t +σ 2 B For (5.27) , it suffices to show that, for any δ > 0 small enough, with probability one for m large enough we have 
